4-{[1-methyl-2,4-dioxo-6-(3-phenylprop-1-yn-1-yl)-1,4-dihydroquinazolin-3(2H)-yl]methyl}benzoic acid

This compound is a synthetic small molecule belonging to the quinazoline class. It was developed as a highly selective inhibitor of matrix metalloproteinase‐13 (MMP13), an enzyme involved in the degradation of type II collagen in articular cartilage. Excess MMP13 activity is implicated in cartilage damage and osteoarthritis. Unlike previous MMP inhibitors that bind to the catalytic zinc ion and often cause musculoskeletal side effects due to lack of selectivity, this compound acts as a noncompetitive inhibitor with respect to substrate binding and does not bind the catalytic zinc ion directly. In preclinical studies (notably by Pfizer), it demonstrated oral bioavailability and efficacy in reducing cartilage damage without inducing joint fibroplasia or other musculoskeletal syndrome side effects typical of less selective MMP inhibitors. The compound has been used experimentally for research into disease-modifying osteoarthritis drugs but has not advanced into clinical development or approval for human use[7].

Other names

4-{[1-methyl-2,4-dioxo-6-(3-phenylprop-1-yn-1-yl)-1,4-dihydroquinazolin-3(2H)-yl]methyl}benzoic acid4-{[1-METHYL–2,4-DIOXO–6-(3-PHENYLPROP–1-YN–1-YL)–1,4-DIHYDROQUINAZOLIN–3(2H)–YL]METHYL}BENZOIC ACID451471‑51‑5Benzoic acid, 4‑[[1,4‑dihydro‑1‑methyl‑2,4‑dioxo‑6-(3‑phenylpropynyl)−3(2H)−quinazolinyl]methyl]